Axiom Biosciences Reports Positive Phase 1 Results for Investigational Stem Cell Therapy in Newborns with Severe Brain Injury

Phase 1positiveWharton's Jelly-derived mesenchymal stem cell therapyPositive

AI Analysis

Summary

Axiom Biosciences announced positive Phase 1 results for its WJ-MSC stem cell therapy for treating severe neurological conditions in newborns (IVH and HIE), co-developed with Medinno Inc. The therapy showed positive safety and efficacy signals in early human testing.

Clinical Trial Data

Phase

Phase 1

Primary Endpoint

Met

Outcome Details

Positive Phase 1 results for WJ-MSC therapy in neonatal brain injury

Importance:6/10

Sentiment:

0.75

stem cell therapyregenerative medicineneonatalneurological disordersclinical stage

Related Companies

$GBIO $BNN.DE

Read the original article

Published by GlobeNewswire Clinical Studies on July 14, 2026 11:02 AM

Read Original